Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq

Core Viewpoint - Enlivex Therapeutics Ltd. has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) to focus on U.S.-based trading and reduce administrative costs associated with dual listing [1][4]. Group 1: Delisting Process - The last trading day for the ordinary shares on the TASE is expected to be April 23, 2026, with delisting anticipated around April 26, 2026 [2]. - Shareholders will continue to trade ordinary shares on the TASE until the final trading day [2]. - The ordinary shares will continue to be traded on the Nasdaq Capital Market under the symbol "ENLV" [3]. Group 2: Strategic Objectives - The Board of Directors approved the delisting to operate under a single set of listing requirements, which aims to reduce duplicative administrative costs and potentially enhance liquidity on Nasdaq [4]. - The transition allows the company to concentrate its investor and public relations efforts on the U.S. capital markets [4]. Group 3: Company Overview - Enlivex is a clinical-stage biotech company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, a therapy for osteoarthritis [5]. - Osteoarthritis affects over 32.5 million Americans and is projected to impact 78 million by 2040, highlighting a significant market need for effective treatments [6].